CTRP3 and Progranulin in Patients With Coronary Artery Disease

Coronary Artery Disease Clinical Trial

Official title:

Implications of C1q/TNF-related Protein-3(CTRP-3) and Progranulin in Patients With Acutecoronary Syndrome and Stable Angina Pectoris

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01869816
• Other study ID #: CAD(CTRP3,PRGL)
• Status: Completed
• Start date: March 1, 2011
• Est. completion date: December 31, 2012

Study information

• Verified date: August 2020
• Source: Korea University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Visceral obesity is the one of the major causes of cardiovascular morbidity and mortality in industrialized countries. Adipose tissue secretes various kinds of bioactive molecules termed adipokines which contribute to the development of obesity-related disorders including cardiovascular disease (CVD). Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to compare circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well-known CAD risk factors.

Description:

CTRP-3 (synonyms CORS-26, cartducin and cartonectin) is a potent anti-inflammatory adipokine that inhibits proinflammatory pathways in monocytes and adipocytes. Using a recently developed enzymelinked immunosorbent assay (ELISA), we reported that circulating CTRP-3 levels were elevated in patients with glucose metabolism dysregulation.

Progranulin was identified as a key adipokine mediating high fat diet-induced insulin resistance and obesity through interleukin-6 (IL-6) in adipose tissue. We previously reported that progranulin levels were significantly higher in individuals with type 2 diabetes and were associated with macrophage infiltration in omental adipose tissue. Moreover, the expression of progranulin reduces inflammation and its degradation into granulins peptides enhances inflammation in atherosclerotic plaque, which may contribute to the progression of atherosclerosis There has been no previous report on the implication of CTRP-3 or progranulin in humans with cardiovascular disease (CAD). In the present study, we compared circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well known CAD risk factors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 362
• Est. completion date: December 31, 2012
• Est. primary completion date: December 31, 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• acute myocardial infarction

• unstable angina

• stable angina pectoris

Exclusion Criteria:

For control group, we exclude the participants who had

• a history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)

• type 2 diabetes

• stage 2 hypertension (resting blood pressure, =160/100 mmHg)

• malignancy

• severe renal or hepatic disease

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Locations

Country	Name	City	State
Korea, Republic of	Korea University Guro Hospital Dept. of Endocrinology	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Korea University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CTRP3	CTRP3 (ng/ml)	16 months
Secondary	SBP	SBP (mmHg)	16 months
Secondary	LDL cholesterol	LDL (mg/dl)	16 months
Secondary	hsCRP	hsCRP (mg/dl)	16 months
Secondary	creatinine	creatinine (mg/dl)	16 months